Zimbabwe has rejected a significant American health deal worth $367m (£272m) spanning five years because of the United States' demand for confidential data.
This rejection came to light after a government memo dated December was leaked, indicating that President Emmerson Mnangagwa deemed the agreement was "skewed".
An official spokesman has since stated that the United States was seeking health data for scientific study and commercial purposes but was unwilling to guarantee the resulting advantages from any future vaccines.
"We will now turn to the difficult and regrettable process of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had provided over $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for continued talks to find a deal suitable to all parties so the country's critical HIV programme can continue.
Broader Implications
Zimbabwe's decision comes after a similar situation in Kenya, where a high court halted a related health funding agreement following legal challenges were filed about the safety of Kenyans' medical information.
After returning to office last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump stated its expenditure was "inefficient" and his administration was seeking direct bilateral agreements to enhance transparency and accountability.
According to reports, 16 African countries have to date agreed to similar agreements, representing over $18.3bn in new funding.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation might have yielded significant benefits for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy through US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its genetic material and health information for a long time, with no equivalent guarantee of benefiting from any medical innovations – such as new medicines or tests – that might result from that provided information," his statement read.
"In essence, our country would provide the basic resources for medical research with no certainty that the resulting innovations would be accessible to our citizens should a new pandemic emerge."
National Interest and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its push of bilateral deals were disrupting systems previously established through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system designed to manage potential global health emergencies.
"This framework is designed to guarantee that when a nation provides its information, the benefits – such as medicines and cures – are shared equitably, not monopolised solely by those with the capability to develop them."
These objections regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome ongoing discussions with our US partners on how subsequent collaboration might be designed in a way that respects the independence and interests of each country."
Medical Community Response
Medical experts stated it understood the government's concerns, but urged that negotiations need to persist given that a large portion of the nation's HIV programmes relied on foreign aid.
"If technical issues arise, such as those involving data governance or agreement terms, these can frequently be resolved via detailed discussion and mutually agreed protections," it commented.
The situation underscores the ongoing debate between receiving much-needed international aid and safeguarding national sovereignty in an ever more data-driven world.